(DLB) Dolby Laboratories - Ratings and Ratios
Audio, Imaging, Cinema, Software, Hardware
DLB EPS (Earnings per Share)
DLB Revenue
Description: DLB Dolby Laboratories
Dolby Laboratories is a leading provider of audio and imaging solutions for various industries, including television, broadcast, and live entertainment. The companys technologies, such as Dolby Atmos and Dolby Vision, are designed to create immersive audio and video experiences. Dolby Laboratories serves a diverse range of customers, including film studios, content creators, post-production facilities, and broadcasters.
From a business perspective, Dolby Laboratories has a strong presence in the premium cinema market with its Dolby Cinemas offering, which combines Dolby Vision, Dolby Atmos, and a unique theater design. Additionally, the company has expanded into the SaaS market with Dolby.io, a platform that enables real-time engagement for live events. The companys product portfolio also includes digital cinema servers, cinema processors, amplifiers, loudspeakers, and other audio and imaging hardware and software products.
In terms of key performance indicators (KPIs), Dolby Laboratories revenue growth, gross margin, and operating margin are important metrics to track. The companys ability to license its technologies to a wide range of customers and its presence in various markets, including cinema, television, and live entertainment, contribute to its revenue growth. With a market capitalization of $7.2 billion and a forward P/E ratio of 18.55, Dolby Laboratories valuation is relatively reasonable compared to its peers. Furthermore, the companys return on equity (RoE) of 10.27% indicates a decent level of profitability.
To further analyze Dolby Laboratories performance, other relevant KPIs could include its revenue breakdown by segment, customer acquisition costs, and research and development (R&D) expenses as a percentage of revenue. The companys ability to innovate and stay ahead of the competition in terms of audio and imaging technologies will be crucial to its long-term success. With its strong brand recognition and diverse product portfolio, Dolby Laboratories is well-positioned to capitalize on the growing demand for immersive audio and video experiences.
DLB Stock Overview
| Market Cap in USD | 6,975m |
| Sub-Industry | Electronic Components |
| IPO / Inception | 2005-02-17 |
DLB Stock Ratings
| Growth Rating | 1.38% |
| Fundamental | 80.5% |
| Dividend Rating | 57.9% |
| Return 12m vs S&P 500 | -11.7% |
| Analyst Rating | 4.50 of 5 |
DLB Dividends
| Dividend Yield 12m | 1.79% |
| Yield on Cost 5y | 2.17% |
| Annual Growth 5y | 6.93% |
| Payout Consistency | 86.1% |
| Payout Ratio | 32.4% |
DLB Growth Ratios
| Growth Correlation 3m | -43.9% |
| Growth Correlation 12m | -1.9% |
| Growth Correlation 5y | -31.6% |
| CAGR 5y | 3.51% |
| CAGR/Max DD 5y | 0.09 |
| CAGR/Mean DD 5y | 0.19 |
| Sharpe Ratio 12m | -0.62 |
| Alpha | 0.07 |
| Beta | 0.398 |
| Volatility | 21.24% |
| Current Volume | 294.9k |
| Average Volume 20d | 400.5k |
| Stop Loss | 70.1 (-3%) |
| Signal | -1.17 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (264.3m TTM) > 0 and > 6% of Revenue (6% = 80.8m TTM) |
| FCFTA 0.14 (>2.0%) and ΔFCFTA 4.79pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 70.48% (prev 88.46%; Δ -17.98pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.23 (>3.0%) and CFO 747.2m > Net Income 264.3m (YES >=105%, WARN >=100%) |
| Net Debt (-435.1m) to EBITDA (306.4m) ratio: -1.42 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.44 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (95.8m) change vs 12m ago -1.21% (target <= -2.0% for YES) |
| Gross Margin 88.52% (prev 88.72%; Δ -0.20pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 43.66% (prev 42.35%; Δ 1.31pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.11 (EBITDA TTM 306.4m / Interest Expense TTM 34.1m) >= 6 (WARN >= 3) |
Altman Z'' 9.80
| (A) 0.30 = (Total Current Assets 1.34b - Total Current Liabilities 388.8m) / Total Assets 3.20b |
| (B) 0.82 = Retained Earnings (Balance) 2.62b / Total Assets 3.20b |
| warn (B) unusual magnitude: 0.82 — check mapping/units |
| (C) 0.08 = EBIT TTM 242.1m / Avg Total Assets 3.08b |
| (D) 4.43 = Book Value of Equity 2.62b / Total Liabilities 591.3m |
| Total Rating: 9.80 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 80.53
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 6.98% = 3.49 |
| 3. FCF Margin 32.52% = 7.50 |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda data missing |
| 6. ROIC - WACC 13.03% = 12.50 |
| 7. RoE 10.40% = 0.87 |
| 8. Rev. Trend 25.47% = 1.27 |
| 9. Rev. CAGR 4.69% = 0.59 |
| 10. EPS Trend 26.63% = 0.67 |
| 11. EPS CAGR 21.45% = 2.14 |
What is the price of DLB shares?
Over the past week, the price has changed by +0.26%, over one month by +1.18%, over three months by -3.81% and over the past year by +6.38%.
Is Dolby Laboratories a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DLB is around 66.12 USD . This means that DLB is currently overvalued and has a potential downside of -8.54%.
Is DLB a buy, sell or hold?
- Strong Buy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the DLB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 103 | 42.5% |
| Analysts Target Price | 103 | 42.5% |
| ValueRay Target Price | 73.1 | 1.1% |
Last update: 2025-08-29 04:36
DLB Fundamental Data Overview
CCE Cash And Equivalents = 698.6m USD (last quarter)
P/E Trailing = 26.6199
P/E Forward = 17.6056
P/S = 5.1782
P/B = 2.6545
P/EG = 2.0755
Beta = 0.903
Revenue TTM = 1.35b USD
EBIT TTM = 242.1m USD
EBITDA TTM = 306.4m USD
Long Term Debt = unknown (0.0)
Short Term Debt = unknown (0.0)
Debt = unknown
Net Debt = -435.1m USD (from netDebt column, last fiscal year)
Enterprise Value = 6.28b USD (6.97b + (null Debt) - CCE 698.6m)
Interest Coverage Ratio = 7.11 (Ebit TTM 242.1m / Interest Expense TTM 34.1m)
FCF Yield = 6.98% (FCF TTM 438.1m / Enterprise Value 6.28b)
FCF Margin = 32.52% (FCF TTM 438.1m / Revenue TTM 1.35b)
Net Margin = 19.62% (Net Income TTM 264.3m / Revenue TTM 1.35b)
Gross Margin = 88.52% ((Revenue TTM 1.35b - Cost of Revenue TTM 154.6m) / Revenue TTM)
Tobins Q-Ratio = 2.40 (Enterprise Value 6.28b / Book Value Of Equity 2.62b)
Interest Expense / Debt = unknown (Interest Expense 34.1m / Debt none)
Taxrate = -15.41% (set to none) (-48.2m / 312.5m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 3.44 (Total Current Assets 1.34b / Total Current Liabilities 388.8m)
Debt / Equity = unknown Debt (none)
Debt / EBITDA = unknown (Net Debt -435.1m / EBITDA 306.4m)
Debt / FCF = none (Debt none / FCF TTM 438.1m)
Total Stockholder Equity = 2.54b (last 4 quarters mean)
RoA = 8.27% (Net Income 264.3m, Total Assets 3.20b )
RoE = 10.40% (Net Income TTM 264.3m / Total Stockholder Equity 2.54b)
RoCE = 9.53% (Ebit 242.1m / (Equity 2.54b + L.T.Debt 0.0))
RoIC = 13.03% (Ebit 242.1m / (Assets 3.20b - Current Assets 1.34b))
WACC = unknown (E(6.97b)/V(0.0) * Re(7.48%)) + (D(none)/V(0.0) * Rd(none%) * (1-Tc(none)))
Shares Correlation 5-Years: -70.0 | Cagr: -1.99%
Discount Rate = 7.48% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 78.41% ; FCFE base≈368.9m ; Y1≈371.9m ; Y5≈400.9m
Fair Price DCF = 115.7 (DCF Value 7.08b / Shares Outstanding 61.2m; 5y FCF grow 0.37% → 3.0% )
Revenue Correlation: 25.47 | Revenue CAGR: 4.69%
Rev Growth-of-Growth: 5.82
EPS Correlation: 26.63 | EPS CAGR: 21.45%
EPS Growth-of-Growth: 45.15
Additional Sources for DLB Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle